L3VLUP
ProSign in

REGN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

REGNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • REGN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterREGNLLY
Q3 202024 holders, $17.4bn33 holders, $14.1bn
Q4 202026 holders, $15.2bn29 holders, $17.3bn
Q1 202122 holders, $13.7bn24 holders, $23.0bn
Q2 202127 holders, $15.3bn24 holders, $27.8bn
Q3 202126 holders, $15.5bn31 holders, $29.9bn
Q4 202128 holders, $16.3bn31 holders, $34.7bn
Q1 202225 holders, $19.2bn24 holders, $35.3bn
Q2 202226 holders, $16.5bn33 holders, $42.7bn
Q3 202224 holders, $19.0bn31 holders, $43.4bn
Q4 202230 holders, $20.2bn31 holders, $46.6bn
Q1 202332 holders, $22.3bn33 holders, $44.3bn
Q2 202328 holders, $18.8bn37 holders, $59.6bn
Q3 202326 holders, $21.1bn44 holders, $67.6bn
Q4 202335 holders, $21.9bn45 holders, $73.6bn
Q1 202428 holders, $23.6bn41 holders, $95.3bn
Q2 202428 holders, $25.6bn43 holders, $110bn
Q3 202431 holders, $25.0bn45 holders, $107bn
Q4 202427 holders, $13.8bn46 holders, $93.9bn
Q1 202529 holders, $12.2bn42 holders, $98.4bn
Q2 202532 holders, $9.3bn43 holders, $93.2bn
Q3 202533 holders, $10.1bn39 holders, $86.7bn
Q4 202533 holders, $16.3bn41 holders, $123bn
Q1 202624 holders, $15.2bn39 holders, $106bn
Q2 202622 holders, $10.6bn44 holders, $132bn
REGN

Regeneron Pharmaceuticals

Holders
32
Reported value
$9.3bn
Buyers
24
Sellers
10

Breadth +14 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only REGN (7)

ARK Investment Management LLC, Bridgewater Associates LP, Scion Asset Management LLC, Southeastern Asset Management Inc, Tudor Investment Corp, Verition Fund Management LLC, Voloridge Investment Management LLC

Only LLY (18)

Artisan Partners LP, Brevan Howard Capital Management LP, Coatue Management LLC, ExodusPoint Capital Management LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Janus Henderson Group Ltd, Maverick Capital Ltd, MFS Investment Management, Moore Capital Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Tiger Global Management LLC, Viking Global Investors LP, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →